Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: A 10 year study

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 1010-1015

  Lafaurie, Matthieu ^a   Porcher, Raphael ^a   Donay, Jean Luc ^a   Touratier, Sophie ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Antibiotic stewardship; Interrupted times series; Resistance

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; DISEASE SURVEILLANCE; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUASI EXPERIMENTAL STUDY; TERTIARY HEALTH CARE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FLUOROQUINOLONES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 84858690274     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr555     Document Type: Article

References (31)

1. Muller AA, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003; 36: 971-8.
2. Loeb MB, Craven S, McGeer AJ et al. Risk factors for resistance to antimicrobial agents among nursing home residents. Am J Epidemiol 2003; 157: 40-7.
3. Livermore DM. Minimising antibiotic resistance. Lancet Infect Dis 2005; 5: 450-9.
4. Goettsch W, van Pelt W, Nagelkerke N et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46: 223-8.
5. Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37: 1643-8.
6. Harbarth S, Liassine N, Dharan S et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-5.
7. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerging Infect Dis 2003; 9: 1415-22.
8. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8.
9. Gasink LB, Fishman NO, Weiner MG et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006; 119: 526.e19-25.
10. Hsu DI, Okamoto MP, Murthy R et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005; 55: 535-41.
11. Polk RE, Johnson CK, McClish D et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39: 497-503.
12. Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 441-9.
13. Carling P, Fung T, Killion A et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706.
14. Gottesman BS, Carmeli Y, Shitrit P et al. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009; 49: 869-75.
15. Patterson JE, Hardin TC, Kelly CA et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-8.
16. Davey P, Brown E, Fenelon L et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; issue 4: CD003543.
17. Charbonneau P, Parienti J, Thibon P et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006; 42: 778-84.
18. Jarlier V, Trystram D, Brun-Buisson C et al. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med 2010; 170: 552-9.
19. Shardell M, Harris AD, El-Kamary SS et al. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007; 45: 901-7.
20. Hennessy TW, Petersen KM, Bruden D et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis 2002; 34: 1543-50.
21. Ray WA, Schaffner W, Federspiel CF. Persistence of improvement in antibiotic prescribing in office practice. JAMA 1985; 253: 1774-6.
22. Seppälä H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
23. Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
24. Monnet DL, López-Lozano JM, Campillos P et al. Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models. Clin Microbiol Infect 2001; 7 Suppl 5: 29-36.
25. Aldeyab MA, Monnet DL, López-Lozano JM et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62: 593-600.
26. MacKenzie FM, Bruce J, Struelens MJ et al. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect 2007; 13: 269-76.
27. Madaras-Kelly KJ, Remington RE, Lewis PG et al. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006; 27: 155-69.
28. Harbarth S, Samore MH. Interventions to control MRSA: high time for time-series analysis? J Antimicrob Chemother 2008; 62: 431-3.
29. Parienti JJ, Cattoir V, Thibon P et al. Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis. J Hosp Infect 2011; 78: 118-22.
30. Aubert G, Carricajo A, Vautrin A et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 2005; 59: 83-9.
31. Gruson D, Hilbert G, Vargas F et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162: 837-43.